Founders Capital Management boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 31.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 105,739 shares of the biopharmaceutical company’s stock after buying an additional 25,403 shares during the period. Pfizer accounts for 3.0% of Founders Capital Management’s investment portfolio, making the stock its 10th largest position. Founders Capital Management’s holdings in Pfizer were worth $3,799,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Heritage Way Advisors LLC raised its position in Pfizer by 0.6% in the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock valued at $2,492,000 after purchasing an additional 354 shares during the period. Natixis purchased a new stake in shares of Pfizer in the 2nd quarter valued at $258,466,000. Machina Capital S.A.S. raised its holdings in shares of Pfizer by 14.4% in the 2nd quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock valued at $1,899,000 after buying an additional 5,522 shares during the period. M Holdings Securities Inc. raised its holdings in shares of Pfizer by 27.9% in the 1st quarter. M Holdings Securities Inc. now owns 39,851 shares of the biopharmaceutical company’s stock valued at $1,692,000 after buying an additional 8,693 shares during the period. Finally, Integrated Wealth Concepts LLC raised its holdings in shares of Pfizer by 14.2% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock valued at $2,840,000 after buying an additional 8,445 shares during the period. 71.69% of the stock is currently owned by institutional investors.
Several equities research analysts recently issued reports on PFE shares. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a report on Tuesday, October 1st. Morgan Stanley cut their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 27th. Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. boosted their price objective on Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. Twelve equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $45.20.
In other Pfizer news, Director Scott Gottlieb acquired 3,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now owns 3,000 shares in the company, valued at approximately $104,160. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Pfizer Inc acquired 50,000 shares of the stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
NYSE PFE traded up $0.14 during trading hours on Thursday, hitting $35.83. 5,392,233 shares of the company were exchanged, compared to its average volume of 20,235,098. The company has a 50 day moving average of $35.92 and a two-hundred day moving average of $40.00. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $46.47. The firm has a market cap of $198.18 billion, a price-to-earnings ratio of 11.94, a PEG ratio of 2.85 and a beta of 0.66.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the business earned $0.77 EPS. Pfizer’s revenue was down 1.5% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.81 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 annualized dividend and a dividend yield of 4.02%. Pfizer’s dividend payout ratio is currently 48.00%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: Consumer behavior in bull markets
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.